AzTrials
AzTrials

Type 2 DiabetesNCT05986097

The Breakfast Study

A study testing Breakfast in people with Type 2 Diabetes, run by University of Michigan at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Type 2 Diabetes
What is being tested?
Breakfast
Could I receive a placebo?
No, everyone receives an active treatment
How many people
119 participants
Where
1 siteUnited States
Study dates
2 Aug 2023to 17 Oct 2025
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • HbA1c 7% or higher
  • 18-80 years old
  • The ability to understand verbal and written English
  • Willingness to follow the prescribed diet
  • Able to consent and follow directions
  • Willingness to regularly check blood glucose levels as required

Who cannot join

  • Inability to provide informed consent
  • Pregnant, breastfeeding, or planning for either in the next 6 months or <6 months postpartum
  • Low C-peptide and possible subsequent GAD 65 level that suggests type 1 diabetes, clinical factors that suggest type 1 diabetes (lean, lack of family history, and diabetic ketoacidosis in the past) or a previous diagnosis of type 1 diabetes or latent autoimmune diabetes
  • Triglycerides are greater than 999mg/dL on the screening blood draw
  • Cancer, heart failure, or kidney failure
  • Vegan
Show all 14Show fewer
  • Untreated mental health condition
  • Currently following a very low-carbohydrate diet or breakfasts
  • Thyroid levels out of range
  • Alcoholism
  • Previous bariatric surgery
  • Difficulty chewing or swallowing
  • Dependence on others for food preparation
  • Currently enrolled in another investigative study that might conflict with this research

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Michigan

    Ann Arbor, Michigan, 48109

Other trials in United States

About this study

Official title: The Breakfast Study: A Small Steps, Low-literacy, Breakfast-focused Dietary Self-management Intervention for Adults With Poorly Controlled Type 2 Diabetes

The investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.

Read the detailed description

More than 15% of U.S. adults with type 2 diabetes have poorly controlled blood glucose, here defined as a glycated hemoglobin (HbA1c) level of 7.0% or higher. These adults have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes. Nutrition- focused interventions can be effective for improving glycemic control, reducing anti-hyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes. However, typical nutrition-focused interventions can be burdensome, often requiring complex instructions and a complete overhaul of one's diet. Additionally, adults with poorly controlled type 2 diabetes are more likely to have low literacy levels, which can be a barrier for adherence to complex interventions. Therefore, an effective intervention for adults with poorly controlled diabetes who may have lower health literacy levels is necessary to reduce both HbA1c levels and anti-hyperglycemic medications. Carbohydrate intake has the strongest impact on post-prandial glycemia of any dietary factor, and a very low-carbohydrate diet-due to its ability to improve glycemic control-is now recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes. The investigators hypothesized that some of the benefits of a very low-carbohydrate diet may be available to individuals who change only their breakfasts to be very low-carbohydrate, rather than modifying their entire diet.

Thus, the investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, small- steps, low-literacy, very low-carbohydrate breakfast-focused program in 120 adults with poorly controlled type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.

The investigators also tested whether factors such as sex, health literacy level, and baseline insulin resistance significantly moderate the impact of the intervention on change in HbA1c and change in anti-hyperglycemic medications.

Conditions
Type 2 Diabetes
Being tested
Breakfast
Keywords
Very low carbohydrate diet, Nutrition therapy
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BreakfastBehavioural

    Participants were provided recipes and information to support this dietary change.

Study groups in NCT05986097
Study groupRoleWhat they receive
Very low-carbohydrate breakfastExperimentalMaterials encouraged eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.
Receives: Behavioral: Breakfast

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intervention Satisfaction

    A 1-item measure about intervention satisfaction. We asked participants, "How would you rate your overall satisfaction with the program?" The item was rated from 1 = very dissatisfied to 6 = very satisfied, with higher scores reflecting greater satisfaction.

    Measured: At 4 months

  2. Assessment of Program Feasibility

    For feasibility, the percentage of completed sessions out of 16 possible sessions was calculated for each participant, and the mean percentage across participants was reported.

    Measured: At Month 4

Secondary outcomes (11)
  1. Weekly Dietary Adherence

    A 1-item measure about dietary adherence. We asked participants to reflect on the past week and rate whether they ate a low-carbohydrate breakfast. The item was rated from 1 = not at all to 7 = very much so, with higher scores reflecting greater adherence. Dietary adherence was collected weekly over the 4-month intervention. Average adherence across the intervention was reported.

    Measured: Weekly over 4 months

  2. Change in PROMIS Sleep Disturbance T-score

    The 4-item PROMIS sleep disturbance subscale measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting more severe sleep problems. To assess the effect of dietary change on sleep disturbance, the change in PROMIS sleep disturbance T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  3. Change in PROMIS Pain Interference T-score

    The 4-item PROMIS subscale for pain interference measures the extent to which patients experience problems with pain interference over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater pain interference. To assess the effects of dietary changes on pain, the change in PROMIS pain interference T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  4. Change in PROMIS Anxiety T-score

    The 4-item PROMIS subscale for anxiety measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on anxiety, the change in PROMIS anxiety T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  5. Change in PROMIS Depression T-score

    The 4-item PROMIS subscale for depression measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on depression, the change in PROMIS depression T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  6. Change in PROMIS Fatigue T-score

    The 4-item PROMIS subscale for fatigue measures the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater fatigue. To assess the effects of dietary changes on fatigue, the change in PROMIS fatigue T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  7. Change in PROMIS Physical Function T-score

    The 4-item PROMIS subscale for physical function measures the extent to which patients experience problems with physical function over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better physical function. To assess the effects of dietary changes on physical function, the change in PROMIS physical function T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  8. Change in PROMIS Social Roles T-score

    The 4-item PROMIS subscale for social roles measures the extent to which patients experience problems with their social roles over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better social roles. To assess the effects of dietary changes on social roles, the change in PROMIS social roles T-scores from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  9. Change in PROMIS Pain Intensity

    The 1-item PROMIS subscale for pain intensity measures average pain intensity over the past 7 days using a 10-point Likert scale, with higher scores reflecting greater pain. To assess the effects of dietary changes on pain intensity, the change in PROMIS pain intensity score from baseline to 4 months was evaluated.

    Measured: Baseline, 4 months

  10. Change in HbA1c

    HbA1c is the proportion of hemoglobin in the blood that has glucose attached to it relative to total hemoglobin. It reflects average blood glucose levels over approximately the previous 2-3 months. To assess the effect of dietary change on HbA1c, the change in HbA1c from baseline to 4 months were evaluated. A negative change indicates an improvement in HbA1c from baseline.

    Measured: Baseline, 4 months

  11. Change in Anti-hyperglycemic Medications

    The Medication Effect Score (MES) quantifies the overall intensity of antiglycemic therapy based on potency and dosages of medications (Alexopoulos et al., 2021), with higher scores indicating greater medication intensity. It is interpreted as the reduction in HbA1c attributable to the medication regime. For each diabetes medication, the percentage of the maximum recommended daily dose is multiplied by an adjustment factor reflecting its expected hemoglobin A1c-lowering potency; these values are summed to yield the total MES. Scores range from 0 upward (no fixed maximum), with lower scores reflecting lower medication intensity. The change in MES from baseline to 4 months was evaluated, with negative values indicating a reduction in medication intensity.

    Measured: Baseline, 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2023
  2. Study start2 Aug 2023
  3. Primary completion9 Oct 2025
  4. Study completion17 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
All participants were provided the same intervention.
Masking
None (open label)
Enrolment
119 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05986097
Sponsor's protocol ID
HUM00225646
Other IDs
5R01DK132099-03
Status last verified
Oct 2026
First submitted
17 Jul 2023
Last updated
19 Oct 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hansen A, Raymond K, Simon A, Kim S, Bayandorian H, Marriott D, Saslow LR. Very Low-Carbohydrate Breakfast Intervention for Adults with Type 2 Diabetes and Persistent Hyperglycemia: Protocol for a Digital, Nonrandomized Pre-Post Study. JMIR Res Protoc. 2026 Jan 28;15:e81041. doi: 10.2196/81041.

    PubMed 41605502

Questions about this trial

What is this clinical trial studying?

A study testing Breakfast in people with Type 2 Diabetes, run by University of Michigan at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intervention Satisfaction (time frame: At 4 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05986097, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
The Breakfast Study (NCT05986097) | AzTrials